Leronlimab Shows Encouraging Survival Data in Metastatic Colorectal Cancer Patients
CytoDyn announced encouraging clinical findings from a compassionate use study of leronlimab in patients with advanced metastatic colorectal cancer...
Jon Napitupulu
Zervimesine Alzheimer’s Study Surpasses 50% Enrollment
Cognition Therapeutics announced that its Phase 2 START Study for Alzheimer’s disease has surpassed 50% enrollment. The study, conducted...
BioXcel Therapeutics Gets Positive Recommendation for Serenity Trial
BioXcel Therapeutics’ independent Data Safety Monitoring Board (DSMB) recommended the continuation of the SERENITY At-Home Phase 3 safety trial...
Positive Phase 2B Results for Treatment-Resistant Depression
Atai Life Sciences and Beckley Psytech announced positive topline results from a Phase 2b trial of BPL-003 (intranasal mebufotenin)...
UK MHRA Approves First-in-Human Trial of RinCell-1 for Hearing Loss
Rinri Therapeutics received approval from the UK MHRA to begin its first-in-human clinical trial for Rincell-1, a regenerative cell...
ReproNovo’s RPN-001 Enters US Phase 2 Trial for Male Infertility
ReproNovo has initiated a Phase 2 clinical trial for RPN-001 (leflutrozole), an oral aromatase inhibitor designed to treat male...
Invivyd & SPEAR Study Group Launch Long COVID Monoclonal Antibody Therapy Research
Invivyd formed the SPEAR Study Group to investigate the potential of monoclonal antibody therapy for Long COVID and Post-Vaccination...
Instil Bio’s AXN-2510 Gets FDA IND Clearance for Phase 1 Solid Tumor Trial
Instil Bio announced FDA clearance of its Investigational New Drug (IND) application for AXN-2510 (’2510), a PD-L1xVEGF bispecific antibody....
New Clinical Trial Data: Vivo Technology Shows Promise in Treating Pediatric Sleep Apnea
A recent multi-center clinical trial published in the European Journal of Pediatrics demonstrated the safety and efficacy of Vivos...
Entera Bio’s EB613 Shows Promising Effects on Bone Health in Post-Menopausal Women
Entera Bio announced that data from its Phase 2 study of EB613, an oral PTH(1-34) treatment for osteoporosis, was...